Medicenna

135 articles about Medicenna

• Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

  4/10/2024

  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 (ABeta-only IL-2 ImmunoTherapY) study.

• Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

  4/9/2024

  Medicenna Therapeutics Corp. presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 super-agonist, in patients with advanced solid tumors, at the 2024 Annual Meeting of the American Association for Cancer Research held in San Diego, CA, on April 9th, 2024.

• Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

  4/4/2024

  Medicenna Therapeutics Corp. announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place at the Metro Toronto Convention Centre in Toronto from April 16-17, 2024.

• Medicenna Announces Appointment of New Auditor

  1/12/2024

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of Superkines, announced the appointment of MNP LLP as auditor.

• Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab

  1/9/2024

  Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced initiation of enrollment in the combination arm of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11.

• Medicenna Extends Period to Exercise Certain Warrants - December 22, 2023

  12/22/2023

  Medicenna Therapeutics Corp. announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company originally issued on December 21, 2018.

• Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology

  11/17/2023

  Medicenna Therapeutics Corp. announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp, the Company’s first-in-class IL-4R targeted therapy for the treatment of patients with recurrent glioblastoma, will be presented by Dr. Steven Brem, M.D. at the Society for Neuro-Oncology 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada.

• Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights

  11/14/2023

  Medicenna Therapeutics Corp. today announced financial results and corporate highlights for the second quarter of fiscal 2024, ended September 30, 2023.

• Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

  11/6/2023

  Medicenna Therapeutics Corp. announced that new clinical data from the Phase 1 monotherapy dose escalation/evaluation portion of the Phase 1/2 ABILITY-1 study evaluating MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 super-agonist in clinical development, in patients with advanced solid tumors, were presented at the 38th Annual Meeting of the SITC held in San Diego, CA, on November 4th, 2023.

• Medicenna Announces Nasdaq Delisting and Cutback of Management Team

  10/27/2023

  Medicenna Therapeutics Corp. announced that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC, which notified the Company of the delisting of its securities from the Nasdaq Capital Market as a result of the Company’s failure to comply with the US$1.00 per share minimum bid price requirement.

• Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors

  10/25/2023

  Medicenna Therapeutics Corp. today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, beta-only interleukin-2 (IL-2) super-agonist.

• Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)

  10/24/2023

  Medicenna Therapeutics Corp. announced poster presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer to be held in San Diego, CA, from November 1-5th, 2023.

• Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer

  10/10/2023

  Medicenna Therapeutics Corp. announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer to lead the development strategy and execution of Medicenna’s clinical programs.

• Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

  10/3/2023

  Medicenna Therapeutics Corp. today announced that new preclinical data characterizing MDNA223, an anti-PD1-IL-2 BiSKIT (Bifunctional SuperKine for ImmunoTherapy), were presented at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy held from October 1 - 4, 2023, in Toronto, Canada.

• Medicenna to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

  9/28/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held from October 1 - 4, 2023, in Toronto, Canada.

• Medicenna Announces Results of Annual and Special Meeting of Shareholders

  9/28/2023

  Medicenna Therapeutics Corp. announced the voting results from the Company’s annual and special meeting of shareholders held September 28, 2023.

• Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

  8/28/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Jeff Caravella as Chief Financial Officer.

• Medicenna Establishes Boston Presence, Appoints Brent Meadows as Chief Business Officer, and Bolsters Management

  8/14/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Brent Meadows, MBA, as its Chief Business Officer, as part of the Company’s plans to establish a world-class C-suite in Boston, the industry’s largest biotech hub.

• Medicenna Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

  8/9/2023

  Medicenna Therapeutics Corp. today announced a clinical update on the monotherapy dose escalation portion of the first-in-human, Phase 1/2 ABILITY Study in patients with advanced solid tumors, as its drug candidate MDNA11, a beta-only, long-acting IL-2 super-agonist, advances to the monotherapy dose expansion phase.

• Medicenna Appoints Dr. Arash Yavari as Chair of Development Advisory Committee Development Advisory Committee strengthened with the expertise and leadership of Dr. Yavari

  8/8/2023

  Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, announced the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee, a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy.